Patients need further review before at-home Leqembi if they fall outside early Alzheimer's disease, lack confirmed amyloid-beta pathology, or have factors that raise bleeding or ARIA risk. That includes some people with high-risk ApoE genetics, concerning MRI findings, anticoagulant use, new neurologic symptoms, serious allergy history, or difficulty giving injections safely. Leqembi IQLIK is the subcutaneous, or under-the-skin, form of lecanemab. The FDA approved it as the first at-home starting regimen, allowing a patient or caregiver to begin treatment at home after appropriate evaluation and training.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who meets the studied treatment profile?
- Which genetic and MRI findings raise concern?
- Why do anticoagulants require an individual decision?
- When should a home dose wait?
- Is the patient or caregiver ready for home treatment?
Who meets the studied treatment profile?
Leqembi was studied in people with early Alzheimer's disease: mild cognitive impairment or mild dementia. Anyone at a different disease stage needs closer review because the evidence does not establish the same balance of benefits and risks outside that population. Amyloid-beta pathology must also be confirmed before treatment.
Symptoms alone are not enough. The FDA prescribing information identifies both early-stage disease and pretreatment amyloid confirmation as central eligibility requirements. At-home availability does not broaden those criteria. It changes where treatment can begin, not which patients have supporting evidence for its use.
Which genetic and MRI findings raise concern?
People with two copies of the ApoE ε4 gene need genetic-risk counseling and a careful discussion before starting. The label recommends testing because this group experienced ARIA more often in Study 2: 45%, compared with 19% of people with one copy and 13% of noncarriers. ARIA means amyloid-related imaging abnormalities.
It can become serious, life-threatening, or fatal. Baseline MRI findings that call for heightened review include: These findings can signal greater risk of bleeding inside the brain and greater ARIA risk. The prescribing clinician should weigh them before home treatment begins rather than treating the MRI as a routine formality.
- Microhemorrhages
- Superficial siderosis
- Evidence of a previous brain hemorrhage
- Other signs of cerebral amyloid angiopathy
Why do anticoagulants require an individual decision?
Patients taking anticoagulants—often called blood thinners—need an individualized risk review. The FDA approval notice says anticoagulant use was associated with more brain hemorrhages among Leqembi recipients than among placebo recipients and advises caution. The same applies to patients with other reasons for increased intracerebral-hemorrhage risk.
Home injection does not remove this concern because the risk comes from the treatment and the patient's health profile, not the treatment location. Patients and caregivers should make sure the prescribing team has a complete medication list before the first dose. They should not make their own decision to stop an anticoagulant or proceed without a clinician's review.
When should a home dose wait?
A patient who develops possible ARIA symptoms needs prompt clinical review instead of automatically taking the next dose. Warning signs include: MRI-detected moderate or severe ARIA generally requires treatment suspension.
Symptomatic ARIA beyond limited mild cases also generally calls for holding doses until imaging and symptoms resolve under the label's interruption guidance. A different rule applies to serious hypersensitivity. Patients with a history of serious reactions to lecanemab or its ingredients should not receive Leqembi IQLIK; reported serious reactions include angioedema and anaphylaxis.
- Headache or confusion
- Visual changes or dizziness
- Nausea
- Trouble walking
- Seizure
Is the patient or caregiver ready for home treatment?
The ability to perform the injection safely is part of treatment readiness. Prescribers must train the patient or caregiver and periodically reassess whether that person can administer IQLIK safely and adequately, according to the FDA prescribing information for IQLIK. Anyone who cannot reliably follow the injection process needs added support or another administration plan.
Cognitive limitations, caregiver availability, and consistency should be discussed before supplies arrive at home. At-home initiation also has an evidence limitation. The FDA says the subcutaneous form did not have separate large clinical-outcome trials; support came from pharmacologic equivalence and similar amyloid reduction. Readers should understand that distinction when discussing expected benefits and uncertainties with the prescribing team.
